Post by Donic Chien-Sheng Lu

"𝐖𝐡𝐲 𝐎𝐫𝐠𝐚𝐧-𝐨𝐧-𝐚-𝐂𝐡𝐢𝐩 𝐢𝐬 𝐭𝐡𝐞 '𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐃𝐞𝐟𝐞𝐧𝐬𝐞' 𝐟𝐨𝐫 𝐂𝐑𝐎𝐬 𝐚𝐧𝐝 𝐭𝐡𝐞 '𝐒𝐮𝐜𝐜𝐞𝐬𝐬 𝐄𝐧𝐠𝐢𝐧𝐞' 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚." Despite decades of advancement, 𝐧𝐞𝐚𝐫𝐥𝐲 𝟗𝟎% 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬 that enter clinical trials fail to reach approval. The industry is at a crossroads. Traditional animal testing is becoming an "𝐨𝐮𝐭𝐝𝐚𝐭𝐞𝐝 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝" of high risk and low predictability. With the 𝐅𝐃𝐀 𝐌𝐨𝐝𝐞𝐫𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐀𝐜𝐭 𝟑.𝟎 green-lighting new approach methodologies, providing only animal data is now synonymous with providing high-risk data. 𝐎𝐫𝐠𝐚𝐧-𝐨𝐧-𝐚-𝐂𝐡𝐢𝐩 (𝐎𝐨𝐂): 𝐓𝐡𝐞 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥 𝐃𝐞𝐟𝐞𝐧𝐬𝐞 For CROs, an OoC platform is no longer an "extra expense"—it is a strategic necessity. 𝐇𝐮𝐦𝐚𝐧-𝐂𝐞𝐧𝐭𝐫𝐢𝐜: The leading standard for human physiological simulation. 𝐃𝐞𝐜𝐢𝐬𝐢𝐯𝐞 𝐒𝐲𝐧𝐞𝐫𝐠𝐲: Use OoC to obtain decisive results first, followed by more precise, targeted animal testing. This reduces waste and accelerates timelines. 𝐅𝐮𝐭𝐮𝐫𝐞-𝐏𝐫𝐨𝐨𝐟: Transition from a "testing vendor" to a "risk-reduction partner." Stop reinforcing the 90% failure rate. It’s time to provide human-relevant certainty. #Anivance #Biotech #CRO #FDA #OrganOnAChip #DrugDiscovery #Innovation #Pharma "𝐓𝐡𝐞 𝐛𝐫𝐢𝐝𝐠𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐚 𝟗𝟎% 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐫𝐚𝐭𝐞 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐜𝐞𝐫𝐭𝐚𝐢𝐧𝐭𝐲 𝐢𝐬𝐧'𝐭 𝐣𝐮𝐬𝐭 𝐚 𝐧𝐞𝐰 𝐭𝐨𝐨𝐥—𝐢𝐭'𝐬 𝐚 𝐧𝐞𝐰 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝."